FDA opioid-approval conflicts and industry influence

The agency responsible for deciding which drugs could reach the public was facing questions of its own.

According to claims reported about the FDA’s opioid approval process, some officials had accused the agency of manipulating approvals in ways that could benefit major pharmaceutical companies. Even more concerning was the allegation that the FDA division responsible for approving opioids had, since the 1990s, relied on the pharmaceutical industry for roughly 75% of its funding.

That raised an uncomfortable question , how independent can a regulator be when much of its funding comes from the industry it is supposed to regulate?

There were also allegations of “pay to play” arrangements involving FDA officials, adding another layer to the concerns surrounding the approval process.

These claims were reported as allegations and criticisms of the agency, not as established legal findings in the source material. Still, the possibility of financial dependence influencing decisions involving powerful opioids was enough to raise serious questions about who was really in control of the process.

Source, public reporting on allegations surrounding the FDA’s opioid approval division.